<DOC>
	<DOCNO>NCT00206635</DOCNO>
	<brief_summary>The purpose follow-up study look carefully long-term course multiple sclerosis ( MS ) possibly long-term effect Betaseron patient previously enrol original North American study lead marketing approval Betaseron .</brief_summary>
	<brief_title>Betaseron 16-Year Long-Term Follow-Up ( LTF ) Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc. sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients North America previously enrol original Betaseron trial 19881993 Be able understand consent form ( guardian ) North American patient include participated original Betaseron trial 19881993</criteria>
	<gender>All</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>